Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL

Journal of Lipid Research

Volumn 56, Issue 3, 2015, Pages 635-643

  Tavori, Hagai ^a   Su, Yan Ru ^b   Yancey, Patricia G ^c   Giunzioni, Ilaria ^a   Wilhelm, Ashley J ^b,c   Blakemore, John L ^b   Zabalawi, Manal ^c   Linton, MacRae F ^b   Sorci Thomas, Mary G ^c   Fazio, Sergio ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein AI; Bone marrow transplant; Gene therapy; Hematopoietic progenitor cells; High density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; CD4 ANTIGEN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LENTIVIRUS VECTOR; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DERMATITIS; DYSLIPIDEMIA; DYSLIPIDEMIA INDUCED DERMATITIS; FEMALE; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPERCHOLESTEROLEMIA; LIPID DIET; LYMPHATIC DRAINAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN STRUCTURE; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DERMATITIS; GENE EXPRESSION REGULATION; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MICE, KNOCKOUT;

EID: 84925238577     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M056408     Document Type: Article

References (53)

1. Castelli, W. P., R. J. Garrison, P. W. Wilson, R. D. Abbott, S. Kalousdian, and W. B. Kannel. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J. Am. Med. Assoc. 256: 2835-2838.
2. Assmann, G., P. Cullen, and H. Schulte. 1998. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur. Heart J. 19 (Suppl. A): A2-11.
3. Rosenson, R. S., H. B. Brewer, Jr., W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X. C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125: 1905-1919.
4. Maxfield, F. R., and I. Tabas. 2005. Role of cholesterol and lipid organization in disease. Nature. 438: 612-621.
5. Sirtori, C. R., L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M. L. Muiesan, et al. 2001. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 103: 1949-1954.
6. Hirano, K., S. Yamashita, Y. Kuga, N. Sakai, S. Nozaki, S. Kihara, T. Arai, K. Yanagi, S. Takami, M. Menju, et al. 1995. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15: 1849-1856.
7. Kingwell, B. A., M. J. Chapman, A. Kontush, and N. E. Miller. 2014. HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 13: 445-464.
8. Mohammadpour, A. H., and F. Akhlaghi. 2013. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin. Pharmacokinet. 52: 615-626.
9. Rader, D. J., and G. K. Hovingh. 2014. HDL and cardiovascular disease. Lancet. 384: 618-625.
10. Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat. 2009. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50 (Suppl.): S189-S194.
11. Wang, L., B. G. Sharifi, T. Pan, L. Song, A. Yukht, and P. K. Shah. 2006. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J. Am. Coll. Cardiol. 48: 1459-1468.
12. Major, A. S., D. E. Dove, H. Ishiguro, Y. R. Su, A. M. Brown, L. Liu, K. J. Carter, M. F. Linton, and S. Fazio. 2001. Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice. Arterioscler. Thromb. Vasc. Biol. 21: 1790-1795.
13. Ishiguro, H., H. Yoshida, A. S. Major, T. Zhu, V. R. Babaev, M. F. Linton, and S. Fazio. 2001. Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo. J. Biol. Chem. 276: 36742-36748.
14. Su, Y. R., H. Ishiguro, A. S. Major, D. E. Dove, W. Zhang, A. H. Hasty, V. R. Babaev, M. F. Linton, and S. Fazio. 2003. Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters. Mol. Ther. 8: 576-583.
15. Bielicki, J. K., M. R. McCall, and T. M. Forte. 1999. Apolipoprotein A-I promotes cholesterol release and apolipoprotein E recruitment from THP-1 macrophage-like foam cells. J. Lipid Res. 40: 85-92.
16. Kockx, M., K. A. Rye, K. Gaus, C. M. Quinn, J. Wright, T. Sloane, D. Sviridov, Y. Fu, D. Sullivan, J. R. Burnett, et al. 2004. Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J. Biol. Chem. 279: 25966-25977.
17. Su, Y. R., J. L. Blakemore, Y. Zhang, M. F. Linton, and S. Fazio. 2008. Lentiviral transduction of apoAI into hematopoietic progenitor cells and macrophages: applications to cell therapy of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28: 1439-1446.
18. Linton, M. F., and S. Fazio. 2003. Macrophages, inflammation, and atherosclerosis. Int. J. Obes. Relat. Metab. Disord. 27 (Suppl. 3) : S35-S40.
19. Kontush, A., and M. J. Chapman. 2006. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58: 342-374.
20. Li, Q., Z. Zhai, W. Ma, and Z. Qian. 2014. Anti-inflammatory effects of apoprotein AI are mediated via modulating macrophage polarity. Zhonghua. Xin Xue Guan Bing Za Zhi. 42: 132-135.
21. Yin, K., S. L. Tang, X. H. Yu, G. H. Tu, R. F. He, J. F. Li, D. Xie, Q. J. Gui, Y. C. Fu, Z. S. Jiang, et al. 2013. Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(-/-) mice possibly via activated STAT3-mediated upregulation of tristetraprolin. Acta Pharmacol. Sin. 34: 837-846.
22. Feingold, K. R. 2013. Innate immunity stimulates permeability barrier homeostasis. J. Invest. Dermatol. 133: 1925-1927.
23. Di Nardo, A., P. Wertz, A. Giannetti, and S. Seidenari. 1998. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm. Venereol. 78: 27-30.
24. Mancini, G. B., S. Chan, J. Frohlich, L. Kuramoto, M. Schulzer, and D. Abbott. 2002. Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction. Am. J. Cardiol. 89: 1313-1316.
25. Zabalawi, M., M. Bharadwaj, H. Horton, M. Cline, M. Willingham, M. J. Thomas, and M. G. Sorci-Thomas. 2007. Infl ammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance? J. Lipid Res. 48: 52-65.
26. Zabalawi, M., S. Bhat, T. Loughlin, M. J. Thomas, E. Alexander, M. Cline, B. Bullock, M. Willingham, and M. G. Sorci-Thomas. 2003. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am. J. Pathol. 163: 1201-1213.
27. Wilhelm, A. J., M. Zabalawi, J. S. Owen, D. Shah, J. M. Grayson, A. S. Major, S. Bhat, D. P. Gibbs, Jr., M. J. Thomas, and M. G. Sorci-Thomas. 2010. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J. Biol. Chem. 285: 36158-36169.
28. Wilhelm, A. J., M. Zabalawi, J. M. Grayson, A. E. Weant, A. S. Major, J. Owen, M. Bharadwaj, R. Walzem, L. Chan, K. Oka, et al. 2009. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler. Thromb. Vasc. Biol. 29: 843-849.
29. Tavori, H., D. Fan, I. Giunzioni, L. Zhu, M. F. Linton, A. B. Fogo, and S. Fazio. 2014. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. J. Lipid Res. 55: 2073-2081.
30. Paigen, B., D. Mitchell, K. Reue, A. Morrow, A. J. Lusis, and R. C. LeBoeuf. 1987. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc. Natl. Acad. Sci. USA. 84: 3763-3767.
31. Kaluzny, M. A., L. A. Duncan, M. V. Merritt, and D. E. Epps. 1985. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J. Lipid Res. 26: 135-140.
32. Tavori, H., D. Fan, J. L. Blakemore, P. G. Yancey, L. Ding, M. F. Linton, and S. Fazio. 2013. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 127: 2403-2413.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285: 2486-2497.
34. Vaya, J., A. Szuchman, H. Tavori, and Y. Aluf. 2011. Oxysterols formation as a reflection of biochemical pathways: summary of in vitro and in vivo studies. Chem. Phys. Lipids. 164: 438-442.
35. Moore, K. J., F. J. Sheedy, and E. A. Fisher. 2013. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13: 709-721.
36. Singaraja, R. R., C. Fievet, G. Castro, E. R. James, N. Hennuyer, S. M. Clee, N. Bissada, J. C. Choy, J. C. Fruchart, B. M. McManus, et al. 2002. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110: 35-42.
37. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
38. Li, X. M., W. H. Tang, M. K. Mosior, Y. Huang, Y. Wu, W. Matter, V. Gao, D. Schmitt, J. A. Didonato, E. A. Fisher, et al. 2013. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33: 1696-1705.
39. Accad, M., S. J. Smith, D. L. Newland, D. A. Sanan, L. E. King, Jr., M. F. Linton, S. Fazio, and R. V. Farese, Jr. 2000. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J. Clin. Invest. 105: 711-719.
40. Zawydiwski, R., D. L. Sprecher, M. J. Evelegh, P. Horsewood, C. Carte, and M. Patterson. 2001. A novel test for the measurement of skin cholesterol. Clin. Chem. 47: 1302-1304.
41. Aparicio-Vergara, M., R. Shiri-Sverdlov, G. de Haan, and M. H. Hofker. 2010. Bone marrow transplantation in mice as a tool for studying the role of hematopoietic cells in metabolic and cardiovascular diseases. Atherosclerosis. 213: 335-344.
42. Felfly, H., and G. G. Haddad. 2014. Hematopoietic stem cells: potential new applications for translational medicine. J. Stem Cells. 9: 163-197.
43. Vedhachalam, C., V. Narayanaswami, N. Neto, T. M. Forte, M. C. Phillips, S. Lund-Katz, and J. K. Bielicki. 2007. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry. 46: 2583-2593.
44. Dove, D. E., M. F. Linton, and S. Fazio. 2005. ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects. Am. J. Physiol. Cell Physiol. 288: C586-C592.
45. Tall, A. R., P. Costet, and N. Wang. 2002. Regulation and mechanisms of macrophage cholesterol efflux. J. Clin. Invest. 110: 899-904.
46. Linton, M. F., J. B. Atkinson, and S. Fazio. 1995. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267: 1034-1037.
47. Linton, M. F., and S. Fazio. 1999. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Curr. Opin. Lipidol. 10: 97-105.
48. Fazio, S., V. R. Babaev, A. B. Murray, A. H. Hasty, K. J. Carter, L. A. Gleaves, J. B. Atkinson, and M. F. Linton. 1997. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc. Natl. Acad. Sci. USA. 94: 4647-4652.
49. Galkina, E., and K. Ley. 2009. Immune and inflammatory mechanisms of atherosclerosis. Annu. Rev. Immunol. 27: 165-197.
50. Yancey, P. G., Y. Ding, D. Fan, J. L. Blakemore, Y. Zhang, L. Ding, J. Zhang, M. F. Linton, and S. Fazio. 2011. Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent. Circulation. 124: 454-464.
51. Murphy, A. J., M. Akhtari, S. Tolani, T. Pagler, N. Bijl, C. L. Kuo, M. Wang, M. Sanson, S. Abramowicz, C. Welch, et al. 2011. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121: 4138-4149.
52. Feingold, K. R. 2009. The outer frontier: the importance of lipid metabolism in the skin. J. Lipid Res. 50 (Suppl.): S417-S422.
53. Feingold, K. R., P. M. Elias, M. Mao-Qiang, M. Fartasch, S. H. Zhang, and N. Maeda. 1995. Apolipoprotein E deficiency leads to cutaneous foam cell formation in mice. J. Invest. Dermatol. 104: 246-250.